Press Release: Alder BioPharmaceuticals : Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine

ALD1910 is Alder's first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraineALD1910 is Alder's first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine